PureTech Health plc

Declaration of Voting Results & Voting Rights Announcements • Aug 1, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4622H

PureTech Health PLC

01 August 2019

PureTech Health plc

Total Voting Rights and Share Capital - Month End Disclosure

Pursuant to DTR 5.6.1 of the Disclosure Guidance and Transparency Rules:

As at 31 July 2019 the issued share capital of PureTech Health plc comprised 282,613,821 Ordinary shares of one pence each.  There were no shares held in treasury.

The total number of voting rights in PureTech Health plc is therefore 282,613,821.

This information may be used by shareholders in their calculations to determine if they are required to notify their interest in, or a change to their interest in, PureTech Health plc under the FCA's Disclosure Guidance and Transparency Rules. 

About PureTech Health plc ("PureTech" or the "Company")

PureTech (LSE: PRTC) is an advanced biopharmaceutical company developing highly differentiated medicines for dysfunctions of the Brain-Immune-Gut (BIG) axis. The company has gained deep insights into the connection between these systems and the resulting role in diseases that have been resistant to established therapeutic approaches. By harnessing this emerging field of human biology, PureTech is developing new categories of medicines with the potential to have great impact on people with serious disorders.

PureTech is advancing a rich pipeline of innovative therapies with an unbiased, nimble, and capital efficient R&D model across its affiliates and its internal R&D pipeline. PureTech's pipeline comprises two dozen product candidates, including several clinical-stage programmes, and one product that has been cleared by the US Food and Drug Administration (FDA). The PureTech pipeline includes ground-breaking platforms and therapeutic candidates that were developed in collaboration with some of the world's leading experts.

PureTech's internal pipeline is centred on lymphatic targeting and tissue-selective immunomodulation for the potential treatment of immune and central nervous system disorders, lymphatic conditions, and cancers.  The Company is advancing multiple platforms to enable oral administration of therapies directly into the lymphatic system, regulate lymphatic flow and function, and target immunosuppressive mechanisms in oncology. For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

Contact:

	PureTech Health	FTI Consulting
	Allison Mead Talbot +1 617 651 3156 amt@puretechhealth.com	Ben Atwell, Rob Winder +44 (0) 20 3727 1000

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

TVRWGUGUMUPBGRG